2024-10-20 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis Report

**Company Overview:** Merck & Co Inc is a global pharmaceutical company known for its diverse portfolio of prescription medicines, vaccines, and animal health products. 

**1. Performance Comparison:**

* **Cumulative Return:** 68.89% (MRK) vs 137.88% (VOO)
* **Performance Gap:** -68.99% (MRK is underperforming VOO by 68.99%)
* **Relative Divergence:** 16.28% (Current performance is in the 16.28% percentile compared to historical performance). 

**2. Recent Price Movements:**

* **Closing Price:** $108.7
* **5-day Moving Average:** $110.02
* **20-day Moving Average:** $111.46
* **60-day Moving Average:** $114.53

**3. Technical Indicators:**

* **RSI:** 33.67 (Indicates potentially oversold conditions)
* **PPO:** -0.01 (Indicates a weak trend, possible consolidation)
* **Delta_Previous_Relative_Divergence:** -17.24 (Short-term downtrend observed)
* **Expected Return:** 0.0% (No expected outperformance compared to S&P 500 in the long term).

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-05 | 2.15 | 16.11 B$ |
| 2024-05-03 | 1.88 | 15.78 B$ |
| 2023-11-03 | 1.87 | 15.96 B$ |
| 2023-08-07 | -2.35 | 15.04 B$ |
| 2024-08-05 | -2.35 | 15.04 B$ |

The most recent earnings (2024-08-05) reported EPS of $2.15, exceeding analysts' estimates.  Revenue of $16.11B was also higher than expected.  Strong performance in the Keytruda and Gardasil franchises contributed to the positive results.  Analysts expect continued growth in the coming quarters.

**5. News and Recent Issues:**

* **Recent Market Outlook:** According to FINBOLD, MRK is facing headwinds from patent expirations for some key drugs, but strong growth in other areas like oncology and vaccines is expected to offset the impact.
* **Analyst Opinions:** Most analysts remain optimistic about MRK's long-term prospects due to a robust pipeline of potential drugs and a strong financial position.
* **Performance Highlights:** MRK's stock has been relatively flat in recent months, but its consistent performance and dividend payouts attract long-term investors.

**6. Summary of Analysis:**

MRK is a large-cap pharmaceutical company with a strong brand and diversified product portfolio. However, its current performance is lagging behind the broader market (VOO) and its recent technical indicators suggest a possible consolidation phase. The company is facing patent expirations for some key drugs, but its robust pipeline and strong financial position offer growth opportunities.  Long-term investors may consider accumulating MRK shares during periods of market weakness, aiming for consistent dividend income and capital appreciation in the long run.

**7. Disclaimer:**

This report is for informational purposes only and should not be construed as financial advice.  The information provided does not constitute an endorsement or recommendation to buy or sell any securities.  It is essential to conduct your own due diligence and consult with a qualified financial advisor before making any investment decisions. 
